Related Experiment Video
Updated: Jul 16, 2026
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
Published on: August 16, 2021
A Short-Course Regimen Containing Delamanid, Bedaquiline and Linezolid for the Treatment of Drug-Resistant
Long Jin1, Xiaolei Zhang1, Huailong Jiang1
1Department of Internal Medicine for Tuberculosis, Infectious Disease Hospital of Heilongjiang Province, Harbin, 150500, People's Republic of China.
Purpose:
To assess the efficacy and safety of delamani (Dlm), bedaquiline (Bdq) and linezolid (Lzd) in multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant tuberculosis (RR-TB).
Patients And Methods:
We retrospectively analyzed the clinical data of 71 patients with MDR/RR-TB. All patients were given a 6-9 month short-course treatment based on Dlm, Bdq and Lzd. Outcomes included treatment success, sputum culture conversion rate and time, clinical and imaging improvement, adverse events (AEs), serious adverse events (SAEs), and QTcF prolongation were recorded. Logistic regression and Cox proportional hazards models were used to identify factors associated with treatment success and time to sputum culture conversion, respectively.
Results:
57.75% of patients were male, and the median (IQR) age of all patients was 42.00 (30.50, 54.00) years. At the end of the treatment, 73.24% of patients achieved a good therapeutic outcome, 85.19% of patients achieved negative sputum culture, and the median (IQR) time for sputum culture to turn negative was 62.50 (28.00, 126.00) days. The clinical symptoms of the patients were all significantly improved (P < 0.001). 94.37% of patients showed lesion absorption, and the proportion of lesion area/volume to the whole lung was significantly reduced (P < 0.001). 36.62% of patients developed any grade AEs, the incidence of grade ≥3 AEs was 8.45%, and one patient (1.41%) developed SAEs, which was grade 4 anemia caused by Lzd. 12.68% of patients experienced prolonged QTcF. Previous history of tuberculosis (OR = 0.188, P = 0.015) and hepatitis B (OR = 0.150, P = 0.038) was associated with non-favorable outcomes. No baseline characteristics were associated with time to sputum culture conversion (P > 0.05).
Conclusion:
The Dlm-Bdq-Lzd regimen demonstrated favorable efficacy and safety in patients with MDR/RR-TB, and may represent a mechanistically distinct, shorter-course alternative to conventional regimens, while potential risks such as prolonged QTcF need to be noted.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:28Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
01:31Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...